Enjaymo (sutimlimab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 1 Disease   2 Trials   2 Trials   136 News 


1234»
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi
    Journal, HEOR:  R (Pubmed Central) -  May 29, 2024   
    No abstract available No abstract available
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness of sutimlimab in cold agglutinin disease. (Pubmed Central) -  May 11, 2024   
    Exploratory threshold analyses showed that significant price reduction (>80%) or time-limited treatment (<18?months) followed by lifelong clinical remission off sutimlimab would allow sutimlimab to become cost-effective. The impact of sutimlimab on health system costs with longer term follow-up data merits future study and consideration through a distributional cost-effectiveness framework.
  • ||||||||||  BC5 - Pharmacology and Clinical Application of Complement Inhibitors (Ballroom B-C) -  Feb 27, 2024 - Abstract #HOPA2024HOPA_69;    
    The impact of sutimlimab on health system costs with longer term follow-up data merits future study and consideration through a distributional cost-effectiveness framework. The focus of this presentation will be on the clinical application of complement inhibitors
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi
    Review, Journal:  Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps. (Pubmed Central) -  Oct 5, 2023   
    In this era, numerous novel therapies are emerging for AIHA, including novel complement inhibitors, such as sutimlimab...It is crucial to incorporate not only clinical characteristics but also biomarkers that are associated with pathophysiological differences and severity, to enhance the accuracy of prediction models and facilitate the selection of the optimal therapeutic approach. Future clinical trials should prioritize the inclusion of severe AIHA patients, particularly in the quest for rapidly acting novel agents.
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi, Soliris (eculizumab) / AstraZeneca
    Journal:  Novel therapeutic agents for hemolytic anemia (Pubmed Central) -  Oct 4, 2023   
    In addition, the anti-C1s antibody sutimlimab was approved last year for the treatment of cold agglutinin disease, a form of autoimmune hemolytic anemia. This presentation overviews novel anti-complement agents for these hemolytic anemias.
  • ||||||||||  Review, Journal:  Novel therapeutics and future directions for refractory immune thrombocytopenia. (Pubmed Central) -  Sep 26, 2023   
    This manuscript offers an in-depth review of the current available data for novel therapeutics in ITP presently undergoing phase 2 or 3 studies in patients with heavily pretreated or refractory ITP. It additionally highlights the future directions for drug development in refractory ITP, including discussion of innovative clinical trial designs, health-related quality of life as an indispensable clinical trial end-point and balancing potential toxicities of drugs with their potential benefits in a bleeding disorder in which few patients suffer life-threatening bleeding.
  • ||||||||||  Review, Journal:  Molecular pharmacology in complement-mediated hemolytic disorders. (Pubmed Central) -  Aug 7, 2023   
    Finally, aHUS is an indication for complement inhibitors. Eculizumab and ravulizumab have been approved, whilst other C5 inhibitors, and novel lectin pathway inhibitors are under active investigation in this disease.
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi
    Review, Journal:  Complement-directed therapy for cold agglutinin disease: sutimlimab. (Pubmed Central) -  May 31, 2023   
    The beneficial effects of sutimlimab go beyond rapid inhibition of hemolysis and include sustained meaningful improvements in fatigue and quality-of-life measures. Further real-world evidence of the effectiveness and safety of sutimlimab in CAD and cold agglutinin syndrome will be assessed via the CADENCE registry.
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi
    Review, Journal:  Sutimlimab for the Treatment of Cold Agglutinin Disease. (Pubmed Central) -  May 8, 2023   
    A tentative therapeutic algorithm is presented. The choice of therapy for CAD should be based on an individual assessment, and patients requiring therapy should be considered for inclusion in clinical trials.
  • ||||||||||  Review, Journal:  Monoclonal antibodies for treatment of cold agglutinin disease. (Pubmed Central) -  May 2, 2023   
    Future antibody-based treatment approaches for CAD involve the further development of complement-directed antibodies, combination of rituximab and bortezomib, and daratumumab. Non-antibody based prospective treatments may include the use of Bruton tyrosine kinase inhibitors.
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Not Too Hot, Not Too Cold: The Goldilocks of Hemolysis (Walter E. Washington Convention Center, Room 151 A (Street Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_2414;    
    Moreover, this case highlights the nuances of severe hemolytic anemia management in the ICU, with the need to balance neurologic monitoring, temperature control, and transfusion goals for plasmapheresis. Additionally, this case demonstrated the efficacy of Sutimlimab
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Sepsis and Cold Agglutinin Hemolytic Anemia - An Innovative Approach to the Management of Refractory Hemolysis in Critical Illness (Walter E. Washington Convention Center, Room 151 A (Street Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_2400;    
    Therapeutic plasma exchange can be conducted in these patients by ensuring the patient, blood products, and apheresis machine maintain a temperature above which the patient undergoes agglutination (2). In our patient, we employed the aforementioned techniques to achieve safe and effective plasmapheresis that improved the patient
  • ||||||||||  Enjaymo (sutimlimab) / Sanofi
    An Ace in the Hole: Use of Sutimlimab in Secondary Cold Agglutinin Disease Causing Hemodynamic Collapse (Walter E. Washington Convention Center, Room 151 A (Street Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_2396;    
    This case demonstrates that Sutimlimab may be beneficial in secondary CAD, rapidly halting the hemolytic process and reversing CAD-induced shock. Further studies are needed to determine the efficacy of Sutimlimab in critically ill patients with secondary CAD.
  • ||||||||||  Review, Journal:  Recent progress in ITP treatment. (Pubmed Central) -  Mar 2, 2023   
    Agents targeting specific mechanisms are also discussed: sutimlimab (complement inhibitor); rilzabrutinib (BTK inhibitor) and efgartigimod (modified Fc fragment inhibiting FcRn). Only efgartigimod has completed phase 3 investigation.
  • ||||||||||  Review, Journal:  Rise of the planet of rare anemias: An update on emerging treatment strategies. (Pubmed Central) -  Jan 27, 2023   
    PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan)...Finally, the addition of eltrombopag significantly ameliorated AA outcomes, and data regarding the alternative agent romiplostim are emerging. The accelerated evolution of treatment strategies will need further effort to identify the best candidate for each treatment in the precision medicine era.
  • ||||||||||  Journal:  Antibodies to watch in 2023. (Pubmed Central) -  Dec 7, 2022   
    As of mid-November, 12 antibody therapeutics had been granted first approvals in either the United States or European Union (tebentafusp (Kimmtrak), faricimab (Vabysmo), sutimlimab (Enjaymo), relatlimab (Opdualag), tixagevimab/cilgavimab (Evusheld), mosunetuzumab (Lunsumio), teclistamab (TECVAYLI), spesolimab (SPEVIGO), tremelimumab (Imjudo; combo with durvalumab), nirsevimab (Beyfortus), mirvetuximab soravtansine (ELAHERE™), and teplizumab (TZIELD)), including 4 bispecific antibodies and 1 ADC...An additional seven were first approved in China or Japan in 2022, including two bispecific antibodies (cadonilimab and ozoralizumab)...Our data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline grew by ~20% in the past year to include nearly 140 investigational antibody therapeutics that were designed using a wide variety of formats and engineering techniques. Of those in late-stage development, marketing application submissions for at least 23 may occur by the end of 2023, of which 5 are bispecific (odronextamab, erfonrilimab, linvoseltamab, zanidatamab, and talquetamab) and 2 are ADCs (datopotamab deruxtecan, and tusamitamab ravtansine).